IV drug treatment for out-of-hospital cardiac arrest may not improve long-term survival

Nov 24, 2009

Patients with an out-of-hospital cardiac arrest who received intravenous (IV) drug administration during treatment, recommended in life support guidelines, had higher rates of short term survival but no statistically significant improvement in survival to hospital discharge or long-term survival, compared to patients who did not receive IV drug administration, according to a study in the November 25 issue of JAMA.

"Intravenous access and drug administration are integral parts of cardiopulmonary resuscitation (CPR) guidelines. Millions of patients have received epinephrine during advanced cardiac life support (ACLS) with little or no evidence of improved survival to hospital discharge," the authors write. "Epinephrine was an independent predictor of poor outcome in a large epidemiological study, possibly due to toxicity of the drug or CPR interruptions secondary to establishing an intravenous line and drug administration."

Theresa M. Olasveengen, M.D., of Oslo University Hospital, Norway, and colleagues compared outcomes for patients receiving standard ACLS with and without intravenous drug administration during out-of-hospital in Oslo, between May 2003 and April 2008. Of 1,183 patients for whom resuscitation was attempted, 851 were included in the study and randomized to either intervention; 418 patients were in the ACLS with intravenous drug administration group and 433 were in the ACLS with no intravenous drug administration group. The primary outcome for the study was survival to hospital discharge, with other outcomes including 1-year survival and quality of CPR (chest compression rate, pauses, and ventilation rate).

Analysis of the study results indicated that both groups had adequate and similar CPR quality, with few chest compression pauses and with compression and ventilation rates within the guideline recommendations.

"In the intravenous group, 44 of 418 patients (10.5 percent) survived to hospital discharge vs. 40 of 433 (9.2 percent) in the no intravenous group. Survival with favorable neurological outcome was 9.8 percent for the intravenous group and 8.1 percent for the no intravenous group," the authors write. "The cumulative postcardiac arrest survival rate at 7 days was 14.6 percent for patients in the intravenous group vs. 12.8 percent for patients in the no intravenous group, 11.3 percent vs. 8.8 percent, respectively, at 1 month, and 9.8 percent vs. 8.4 percent at 1 year."

The researchers note that after adjustment for ventricular fibrillation, response interval, witnessed arrest, or arrest in a public location, there was no significant difference in survival to hospital discharge for the intravenous group vs. the no intravenous group. "Larger trials examining resuscitation without intravenous access and drug administration, as well as of existing or new drugs, appear to be justified."

More information: JAMA. 2009;302[20]:2222-2229.

Source: JAMA and Archives Journals (news : web)

Explore further: New research demonstrates benefits of national and international device registries

add to favorites email to friend print save as pdf

Related Stories

Early cooling in cardiac arrest may improve survival

Nov 16, 2009

Rapidly cooling a person in cardiac arrest may improve their chance of survival without brain damage, according to research presented at the American Heart Association's Scientific Sessions 2009.

New studies confirm chest compressions alone

Dec 26, 2007

Two large-scale studies published in the Dec. 18 issue of the American Heart Association’s medical journal, Circulation, report that the chances of surviving cardiac arrest are no better – and may be worse – when b ...

Recommended for you

New approach to particle therapy dosimetry

7 hours ago

Researchers at the National Physical Laboratory (NPL), in collaboration with EMRP partners, are working towards a universal approach to particle beam therapy dosimetry.

Supplement maker admits lying about ingredients

Dec 17, 2014

Federal prosecutors say the owner and president of a dietary supplement company has admitted his role in the sale of diluted and adulterated dietary ingredients and supplements sold by his company.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.